GLSI Greenwich LifeSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.45M | $3.56M | $5.21M | $7.59M | $3.27M | $3.42M | $2.27M | $6.16M |
| SG&A expense | $412,695 | $462,931 | $518,190 | $355,194 | $466,926 | $352,838 | $497,602 | $1.93M |
| Operating income | -$5.86M | -$4.02M | -$5.73M | -$7.94M | -$3.73M | -$3.77M | -$2.77M | -$8.08M |
| Net income | -$5.81M | -$3.95M | -$5.66M | -$7.92M | -$3.71M | -$3.75M | -$2.74M | -$8.04M |
| EPS (basic) | -0.40 | -0.27 | -0.39 | — | -0.27 | -0.28 | -0.21 | — |
| EPS (diluted) | -0.40 | -0.27 | -0.39 | — | -0.27 | -0.28 | -0.21 | — |
| Weighted avg. shares (diluted) | 14.68M | 14.62M | 14.57M | — | 13.64M | 13.37M | 13.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.90M | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | $2.75M | $4.09M |
| Current assets | $5.90M | $8.88M | $10.51M | $6.18M | — | — | — | $4.09M |
| Intangibles | — | — | — | — | — | — | $876 | $1,779 |
| Total assets | $5.90M | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | $2.75M | $4.09M |
| Current liabilities | $7.65M | $5.76M | $5.24M | $5.82M | $1.62M | $1.69M | $1.44M | $3.19M |
| Total liabilities | $7.65M | $5.76M | $5.24M | $5.82M | $2.02M | $2.52M | $2.55M | $3.19M |
| Shareholders' equity | -$1.75M | $3.12M | $5.27M | $353,217 | $1.79M | $604,302 | $200,483 | $908,626 |
| Shares outstanding | 14.68M | 14.68M | 14.67M | 14.30M | 13.79M | 13.47M | 13.19M | 13.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.98M | -$1.94M | -$4.70M | -$3.17M | -$2.67M | -$2.23M | -$1.83M | -$1.85M |
| Financing cash flow | $0 | $310,664 | $9.03M | $5.55M | $3.35M | $2.61M | $492,423 | $121,829 |
| Stock-based compensation | $949,692 | $1.48M | $1.54M | $2.17M | $1.54M | $1.54M | $1.54M | $5.47M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.